

# A Brief Review of Drug Delivery System Used in Breast Cancer Therapies

Niyati Shah<sup>1,\*</sup>, Ritu Sapra<sup>2</sup>, Maitry Suthar<sup>3</sup>, Piyushkumar Sadhu<sup>1</sup>, Nisha Mandloi<sup>2</sup>, Mamta Kumari<sup>1</sup>, Chitrali Talele<sup>1</sup>, Chintan Aundhia<sup>1</sup>

<sup>1</sup>Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Piparia, Vadodara, Gujarat, INDIA.

<sup>2</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medi-Caps University, Indore, Madhya Pradesh, INDIA.

<sup>3</sup>Department of Pharmaceutics, Institute of Pharmaceutical Sciences, Parul University, Vadodara, Gujarat, INDIA.

## ABSTRACT

Breast cancer remains a significant global health challenge, necessitating innovative therapeutic approaches to improve patient outcomes. Drug delivery systems have emerged as promising tools to enhance the efficacy and specificity of breast cancer therapies. This comprehensive abstract explores various drug delivery strategies employed in breast cancer treatment, focusing on their mechanisms, advantages, challenges, and recent developments. The abstract begins by outlining the current landscape of breast cancer and the limitations of conventional treatment modalities. It then delves into the diverse classes of drug delivery systems, encompassing nanoparticles-based approaches, targeted delivery systems, stimuli-responsive strategies, and immunotherapy-based systems. The abstract also highlights the significance of combination therapies and addresses the challenges related to drug resistance, toxicity, and biocompatibility. Furthermore, the abstract elucidates recent advances and future perspectives, including personalized drug delivery and the integration of artificial intelligence in optimizing drug delivery systems. Ultimately, this abstract aims to provide a comprehensive and insightful overview of drug delivery systems used in breast cancer therapies, shedding light on the potential of these technologies to revolutionize breast cancer treatment.

**Keywords:** Personalised Drug Delivery, Nanoparticle Based Approach, Breast Cancer, Targeted Drug Delivery.

## Correspondence:

**Niyati Shah**

Assistant Professor, Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Piparia, Vadodara-391760, Gujarat, INDIA.  
Email: niyatishah25594@gmail.com

**Received:** 18-08-2025;

**Revised:** 06-10-2025;

**Accepted:** 24-12-2025.

## INTRODUCTION

Breast cancer is a prevalent and potentially life-threatening disease that primarily affects women but can also occur in men. It originates in the breast tissue, typically as a malignant tumor. This cancer can spread to nearby lymph nodes and, if left untreated, to other parts of the body. Early detection through regular screenings, such as mammograms, is crucial for effective treatment. Breast cancer awareness campaigns and advancements in medical research have improved diagnosis and treatment options, increasing survival rates. Treatment may involve surgery, chemotherapy, radiation, hormone therapy, or targeted therapies, tailored to the individual's specific case. Breast cancer remains a significant global health concern (Peer *et al.*, 2020).

## Breast Cancer: Prevalence and Impact

Breast cancer is one of the most prevalent and impactful forms of cancer globally. It primarily affects women, although it can occur in men, albeit much less frequently. Its prevalence is staggering, with millions of new cases diagnosed each year. The impact of breast cancer on individuals and society is profound. It is a leading cause of cancer-related deaths among women worldwide. The physical, emotional, and financial toll on those diagnosed and their families can be devastating. The disease can lead to surgery, chemotherapy, radiation, and hormone therapy, all of which can have severe side effects. Breast cancer also places a significant burden on healthcare systems due to the costs of diagnosis, treatment, and follow-up care (GM Le *et al.*, 2005). Furthermore, the emotional and psychological toll of breast cancer diagnosis and treatment can be long-lasting, affecting the mental health and quality of life of survivors. Despite these challenges, there have been notable advancements in breast cancer research, leading to improved detection methods and more effective treatments. Early detection through mammography and increased awareness campaigns have contributed to higher survival rates. However, breast cancer remains a critical health concern, emphasizing the ongoing need for research, education, and support for those



DOI: 10.5530/ijpi.20260010

### Copyright Information :

Copyright Author (s) 2026 Distributed under Creative Commons CC-BY 4.0

Publishing Partner : Manuscript Technomedia. [www.mstechnomedia.com]

affected by this disease (Pinto *et al.*, 2002). Conventional breast cancer therapies have significantly improved survival rates and patient outcomes. However, they still face several limitations and challenges (Diana *et al.*, 2020).

### Side Effects

Chemotherapy and radiation therapy, two common conventional treatments, can cause severe side effects such as nausea, fatigue, hair loss, and damage to healthy tissues. These side effects can significantly impact the patient's quality of life (Sourati *et al.*, 2020).

### Resistance

Some breast cancers can become resistant to conventional treatments over time, making it challenging to achieve long-term remission. This resistance can necessitate the exploration of alternative therapies or combination treatments (Nedeljkovic *et al.*, 2019).

### Invasiveness

Surgery, often a primary treatment for breast cancer, can be invasive and result in physical and emotional challenges for patients. Mastectomy, in particular, can have a profound impact on a woman's body image and self-esteem (Sherman *et al.*, 2017).

### Limited Targeting

#### *Personalized Treatment*

Breast cancer is not a single disease but rather a group of diverse subtypes. Tailoring treatment to individual patients based on the specific subtype of breast cancer can be challenging but is essential for optimizing outcomes (Ahmad *et al.*, 2019).

### Late-Stage Detection

Despite advances in screening, some breast cancers are still detected at advanced stages, reducing the effectiveness of treatment options and overall survival rates (Trimboli *et al.*, 2020).

### Cost and Accessibility

The cost of conventional breast cancer treatments, especially newer targeted therapies, can be prohibitively high for many patients. Access to cutting-edge treatments may be limited in some regions or for those without adequate healthcare coverage (National Research *et al.*, 2001).

### Psychological and Emotional Impact

The emotional toll of breast cancer diagnosis and treatment is significant. Managing anxiety, depression, and other psychological challenges can be as crucial as physical treatment (Ganz *et al.*, 2008).

### Survivorship Care

After treatment, survivors may face long-term health challenges and require ongoing care and support. Ensuring comprehensive survivorship care is essential but can be a logistical and resource-intensive challenge (Chow *et al.*, 2020).

### Conventional Breast Cancer Therapies: Limitations and Challenges

Conventional breast cancer therapies have made significant progress in treating the disease, but they still face various limitations and challenges:

Addressing these limitations and challenges requires ongoing research and innovation in breast cancer treatment. Personalized medicine, immunotherapies, and advancements in early detection methods offer hope for more effective, less invasive, and targeted approaches to breast cancer treatment in the future.

Drug delivery systems play a crucial role in breast cancer treatment by improving the efficacy and safety of therapeutic agents. Breast cancer is a complex disease, and effective drug delivery is essential to ensure that medications reach the tumor site, exert their intended effects, and minimize damage to healthy tissues (Afzal *et al.*, 2021). Here are some key aspects of the role of drug delivery systems in breast cancer treatment:

#### Targeted Drug Delivery

Drug delivery systems can be designed to target cancer cells specifically while sparing healthy tissues. Targeted therapies, such as monoclonal antibodies and small molecule inhibitors, can be conjugated with nanoparticles or liposomes to deliver drugs directly to cancer cells. This reduces the risk of systemic side effects and enhances the therapeutic index (Minkot *et al.*, 2009).

#### Enhanced Drug Stability

Some chemotherapeutic agents are inherently unstable and may degrade before reaching their target. Drug delivery systems can encapsulate these drugs within protective carriers, ensuring their stability until they reach the tumor site (Ulldemolins *et al.*, 2021).

#### Prolonged Drug Release

Controlled-release drug delivery systems can release therapeutic agents over an extended period. This approach can help maintain effective drug concentrations within the tumor for a longer duration, reducing the need for frequent dosing and minimizing side effects (Jantzen *et al.*, 2002).

#### Overcoming Drug Resistance

Breast cancer cells can develop resistance to chemotherapy over time. Drug delivery systems can be designed to overcome this resistance by delivering multiple drugs or combination therapies simultaneously. This can target multiple pathways involved

in cancer progression and reduce the likelihood of resistance development (Nuriez *et al.*, 2016).

### Minimizing Systemic Toxicity

Drug delivery systems that target the tumor can minimize the exposure of healthy tissues to these toxic drugs, reducing overall toxicity (Schirmacher *et al.*, 2019).

### Imaging and Diagnosis

Some drug delivery systems incorporate imaging agents or contrast agents to aid in the diagnosis and monitoring of breast cancer. These systems can help physicians visualize the tumor and assess the effectiveness of treatment (Kateb *et al.*, 2011).

### Personalized Medicine

Drug delivery systems can be tailored to individual patients based on their specific cancer type, stage, and genetic characteristics. This approach allows for personalized treatment regimens that are more effective and have fewer side effects (Celho *et al.*, 2010).

### Combination Therapies

Drug delivery systems can enable the delivery of multiple therapeutic agents simultaneously, allowing for combination therapies that target different aspects of breast cancer biology. This approach can enhance treatment outcomes by addressing the heterogeneity of the disease (Lee, *et al.*, 2012) (Table 1).

### Localized Treatment

In some cases, drug delivery systems can be used to enhance the delivery of these treatments to the tumor site, maximizing their effectiveness. Overall, drug delivery systems have significantly advanced breast cancer treatment by improving drug delivery precision, reducing side effects, and increasing the effectiveness of therapeutic agents. These systems continue to be an active area of research and development, with the potential to further enhance the outcomes of breast cancer patients in the future (Ostariska *et al.*, 2021).

## NANOPARTICLES-BASED DRUG DELIVERY SYSTEMS

Nanoparticles deliver drugs precisely, improving efficacy and reducing side effects in cancer treatment and other medical applications.

### Liposomes: Versatile Nanocarriers for Breast Cancer Therapeutics

Liposomes, lipid-based nanoparticles, are versatile carriers in breast cancer treatment. They encapsulate drugs, targeting tumors while minimizing side effects. Their flexibility makes them suitable for various therapies, including chemotherapy, targeted therapy, and immunotherapy, offering promising avenues for

personalized and effective breast cancer therapeutics (Plosker *et al.*, 2008).

### Polymeric Nanoparticles: Engineering Enhanced Drug Delivery Systems

Polymeric nanoparticles are engineered drug delivery systems. Tailored for precise drug release, they improve efficacy, minimize side effects, and enable personalized treatment strategies. These versatile carriers hold promise in advancing breast cancer and other medical therapies (Masood *et al.*, 2016).

### Dendrimers: Tailored Nanoscale Platforms for Precise Drug Delivery

Dendrimers are customizable nanoscale platforms for precise drug delivery. Their well-defined structure allows controlled drug release, enhancing therapeutic efficacy while minimizing side effects. Dendrimers hold great potential for advancing targeted treatments in breast cancer and various medical applications (Vaidya *et al.*, 2018).

### Inorganic Nanoparticles: Theranostic Applications in Breast Cancer

Inorganic nanoparticles have emerged as promising theranostic tools in breast cancer. These nanoparticles, often composed of materials like gold, iron oxide, or silica, offer dual capabilities for therapy and diagnostics (Nuriez *et al.*, 2018).

### Therapeutic Applications

Inorganic nanoparticles can be engineered to carry therapeutic agents, such as chemotherapy drugs or gene therapies.

### Imaging and Diagnosis

Inorganic nanoparticles can serve as contrast agents in various imaging techniques like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), or photoacoustic imaging. They improve the visualization of tumors, aiding in early detection, staging, and monitoring of breast cancer.

### Photothermal Therapy

Some inorganic nanoparticles, like gold nanorods, possess unique properties that allow them to absorb and convert near-infrared light into heat.

### Radiotherapy Enhancements

Inorganic nanoparticles can sensitize cancer cells to radiation therapy, making them more susceptible to radiation-induced damage. This approach can enhance the effectiveness of radiation treatment for breast cancer.

## Drug Release Triggering

Inorganic nanoparticles can be designed to release their payload in response to specific triggers, such as changes in pH, temperature, or light exposure.

## Monitoring Treatment Response

Inorganic nanoparticles can be utilized to track treatment response by binding to specific biomarkers associated with breast cancer.

## Personalized Medicine

Inorganic nanoparticles can be tailored for individual patients based on their unique cancer characteristics, allowing for a personalized approach to breast cancer diagnosis and treatment.

In summary, inorganic nanoparticles hold great promise in the theranostic management of breast cancer, offering multifaceted benefits in terms of targeted therapy, early detection, and monitoring of treatment response. Ongoing research aims to further optimize these nanoparticles for clinical applications, potentially revolutionizing breast cancer care.

## TARGETED DRUG DELIVERY

Targeted drug delivery uses nanoparticles, antibodies, peptides, and more to direct drugs precisely, increasing efficacy while minimizing side effects.

### Passive Targeting: Exploiting the Enhanced Permeability and Retention (EPR) Effect

Passive targeting utilizes the EPR effect in tumors, where leaky blood vessels and poor lymphatic drainage allow nanoparticles to accumulate selectively in cancerous tissues. This effect enhances drug delivery precision (Onzi *et al.*, 2011).

### Active Targeting: Ligand-Mediated Selective Drug Delivery to Breast Cancer Cells

Active targeting employs ligands (molecules or antibodies) that bind to specific receptors on breast cancer cells, enhancing drug delivery precision and uptake while minimizing systemic exposure and side effects.

### Ligand-Receptor Interactions: Unlocking Specific Cellular Internalization Pathways

Ligand-receptor interactions facilitate the selective binding of ligands to receptors on cell surfaces, leading to specific cellular internalization pathways. This process enables targeted drug delivery and therapeutic efficacy (Subhan *et al.*, 2019).

## STIMULI-RESPONSIVE DRUG DELIVERY SYSTEMS

Stimuli-responsive drug delivery systems are designed to release therapeutic agents in response to specific triggers or environmental cues. These systems offer precise control over drug release, improving therapeutic outcomes.

### pH-Sensitive Systems: pH-Responsive Nanoparticles for Intracellular Drug Release

pH-sensitive systems, particularly pH-responsive nanoparticles, are designed to release drugs in response to changes in acidity or alkalinity, with a focus on intracellular drug release. Here's how they work (Gao *et al.*, 2010).

#### Acidity of Tumor Microenvironment

Many solid tumors have a more acidic microenvironment compared to healthy tissues

#### Polymeric Materials

pH-responsive nanoparticles are typically made from polymers or materials that contain pH-sensitive functional groups, such as carboxylic acids or amines.

#### Drug Encapsulation

Therapeutic agents, such as chemotherapy drugs or gene therapies, are encapsulated within the pH-responsive nanoparticles. These drugs are often weakly basic or acidic, allowing them to be retained within the nanoparticles at neutral pH.

#### Intracellular Delivery

Upon reaching the tumor site and being taken up by cancer cells, pH-responsive nanoparticles encounter the lower pH environment inside endosomes or lysosomes.

#### Enhanced Therapeutic Efficacy

By achieving intracellular drug release, pH-sensitive nanoparticles enhance the drug's bioavailability within cancer cells. This targeted approach minimizes systemic exposure and reduces off-target effects, increasing the therapeutic efficacy of the drug.

Overall, pH-responsive nanoparticles are a valuable tool in cancer therapy, enabling precise drug delivery to cancer cells and improving the overall effectiveness of treatment while minimizing side effects.

### Temperatures-Responsive Systems: Hyperthermia-Enhanced Drug Delivery

Hyperthermia-enhanced drug delivery is a specialized approach in the field of drug delivery systems where elevated temperatures are used to improve the targeted delivery of therapeutic agents to specific sites within the body. This technique takes advantage of

the fact that some regions of the body can be selectively heated, often through external means, to enhance drug release and uptake.

### Principle of Hyperthermia

Hyperthermia involves raising the temperature of a specific region or tissue in the body to a level that is higher than the normal body temperature (typically around 42-45°C). This can be achieved through various methods such as radiofrequency, microwave, ultrasound, or laser-based techniques.

Hyperthermia-enhanced drug delivery is an innovative approach that harnesses elevated temperatures to improve the targeted delivery of therapeutic agents. It holds promise in various medical applications, particularly in the treatment of cancer and localized infections, but it also comes with challenges related to temperature control and patient safety that need to be addressed in its implementation (Schlemmer *et al.*, 2004).

### Enzyme-triggered drug delivery

Enzyme-triggered drug delivery systems involve the use of nanocarriers that respond to specific enzymes present in the body to release drugs at precise locations or under particular conditions. These systems are designed to improve drug delivery efficiency and minimize side effects by releasing therapeutic agents only when and where they are needed (Cao *et al.*, 2019). Here's an overview of enzyme-responsive nanocarriers for precise drug release:

#### Principle of Enzyme-Responsive Nanocarriers

Enzymes are biological molecules that catalyze specific chemical reactions in the body. They play a vital role in various physiological processes. Enzyme-responsive nanocarriers are engineered to carry drugs and respond to the presence of specific enzymes by undergoing structural changes, which result in drug release. The nanocarriers can be made from various materials, including lipids, polymers, or nanoparticles, and are often coated or modified with enzyme-sensitive molecules.

#### Enzyme Selection

The choice of enzyme is critical and depends on the targeted site or condition. For instance, in cancer therapy, enzymes overexpressed in tumor tissues, such as Matrix Metalloproteinases (MMPs) or cathepsins, are commonly targeted.

#### Mechanisms of Drug Release

**Cleavage-Based Release:** Enzymes cleave specific chemical bonds within the nanocarrier, leading to the release of the encapsulated drug.

**Conformational Changes:** Enzyme-induced changes in the nanocarrier's structure can expose drug-loaded compartments, allowing drug release.

**Controlled Degradation:** Enzyme-sensitive polymers can be used to form nanocarriers, which degrade upon exposure to the target enzyme, releasing the drug payload (Blum AP *et al.*, 2015).

**Applications:** Cancer Treatment Inflammatory Diseases Diagnosis.

### Challenges and Considerations

**Enzyme Specificity:** Ensuring that the nanocarrier responds only to the target enzyme without interference from other enzymes is crucial.

**Stability:** The stability of the nanocarriers in the bloodstream and their ability to remain intact until they reach the target site must be considered.

**Biocompatibility:** The materials used in nanocarrier construction should be biocompatible and safe for use in the body.

**Research and Development:** Ongoing research aims to refine the design of enzyme-responsive nanocarriers, improve their specificity, and optimize drug release kinetics (Sutton *et al.*, 2007).

## IMMUNOTHERAPY-BASED DELIVERY SYSTEMS

Immunotherapy-based delivery systems are a class of drug delivery systems designed to enhance the effectiveness of immunotherapy treatments. Immunotherapy is a type of cancer treatment that harnesses the body's immune system to fight cancer cells. These delivery systems are engineered to improve the delivery, presentation, and retention of immunotherapeutic agents, such as immune checkpoint inhibitors, vaccines, monoclonal antibodies, and cell-based therapies, to maximize their anti-cancer effects (Huang *et al.*, 2019). Here's an overview of immunotherapy-based delivery systems:

### Enhancing Immune Responses

Immunotherapy-based delivery systems aim to improve the body's immune responses against cancer cells by ensuring that the immunotherapeutic agents are delivered to the right target cells and are presented effectively (Yang *et al.*, 2021).

## Types of Immunotherapy-Based Delivery Systems

### Nanoparticles

Nanoparticle-based carriers can encapsulate immunotherapeutic agents, protecting them from degradation and improving their circulation time. These nanoparticles can be designed to target specific immune cells or tumor microenvironments.

### Liposomes

Liposomes can encapsulate immunotherapeutic drugs and deliver them to the desired location in the body. They can also be surface-modified to target specific cells or tissues.

## Hydrogels

Injectable hydrogels can release immunotherapeutic agents slowly over time, providing sustained immune stimulation.

## Viral Vectors

Viral vectors can be engineered to deliver genes encoding immunotherapeutic proteins directly into cells, enhancing immune responses.

## Cell-Based Therapies

Immunotherapy-based delivery systems can also involve the engineering and delivery of immune cells, such as CAR-T cells (Chimeric Antigen Receptor T cells), to target and eliminate cancer cells.

## Site-Specific Targeting

Immunotherapy-based delivery systems can be designed to target specific sites within the body, such as tumor tissues or lymph nodes, where immune responses are needed most.

## Combination Therapies

These systems may facilitate the combination of different immunotherapeutic agents, such as checkpoint inhibitors and vaccines, to enhance the synergistic effects of multiple treatments.

## Minimizing Side Effects

Precise delivery of immunotherapeutic agents can help minimize off-target effects and reduce the risk of autoimmune reactions associated with immunotherapy (Estva *et al.*, 2019).

## CHEMOTHERAPY AND IMMUNOTHERAPY COMBINATIONS: SYNERGISTIC APPROACHES TO BREAST CANCER TREATMENT

Combining chemotherapy and immunotherapy is an emerging approach in breast cancer treatment that aims to enhance the therapeutic benefits of both treatment modalities. Chemotherapy has long been a mainstay in cancer treatment, while immunotherapy has shown great promise in recent years for various cancers, including breast cancer. When used in combination, these therapies can potentially offer synergistic effects, providing better outcomes for patients (Muenst *et al.*, 2016).

### Rationale for Combination Therapy

#### Addressing Tumor Heterogeneity

**Enhanced Immune Activation:** Overcoming Immune Suppression: Some breast tumors develop mechanisms to evade the immune system. Immunotherapy can help overcome these immune escape mechanisms, making the tumor more susceptible to immune attack.

## Benefits of Combining Chemotherapy and Immunotherapy

**Improved Response Rates:** Combining chemotherapy and immunotherapy can lead to higher response rates, as these treatments target cancer cells through different mechanisms.

**Long-Term Immune Memory:** Immunotherapy can induce long-lasting immune memory, potentially preventing cancer recurrence after treatment.

**Reduced Toxicity:** Lower doses of chemotherapy may be needed when combined with immunotherapy, reducing chemotherapy-related side effects.

**Potential for Immunotherapy Resistance:** Chemotherapy can sensitize cancer cells to immunotherapy, helping to overcome resistance that can develop with immunotherapy alone (Goldhirsch *et al.*, 2011).

## Challenges and Considerations

**Patient Selection:** Identifying which patients are most likely to benefit from combination therapy is crucial. Not all breast cancer subtypes may respond equally, and patient characteristics should be considered.

**Toxicity:** Combining chemotherapy and immunotherapy can increase the risk of side effects and immune-related adverse events. Close monitoring and management are necessary.

**Optimal Sequencing:** Determining the timing and sequence of chemotherapy and immunotherapy administration is an ongoing challenge. This may vary based on individual patient factors.

**Cost and Access:** Some immunotherapies can be expensive, and access to these treatments may be limited in some healthcare settings.

**Research and Clinical Trials:** Ongoing research and clinical trials are essential to refine the best combinations, dosing schedules, and patient selection criteria.

In conclusion, combining chemotherapy and immunotherapy represents a promising approach in breast cancer treatment. By leveraging the strengths of both treatment modalities, it is possible to enhance the immune response against breast cancer cells while mitigating some of the side effects associated with traditional chemotherapy. However, careful patient selection, monitoring, and further research are needed to optimize this approach and maximize its benefits for breast cancer patients (Spring *et al.*, 2015).

## Combining chemotherapy

with Photodynamic Therapy (PDT) is a strategy that has been explored in cancer treatment to overcome drug resistance and address tumor heterogeneity. PDT is a localized and minimally invasive treatment that uses a photosensitizing agent and light

**Table 1: Different Drug Delivery System used in Breast Cancer.**

Drug Delivery System	Description	Examples
Liposomes	Lipid-based vesicles that encapsulate drugs, offering targeted delivery and reduced systemic toxicity.	Doxorubicin liposome (Doxil), DaunoXome
Polymeric Nanoparticles	Nanoparticles made from biodegradable polymers, providing controlled release and targeted drug delivery.	Abraxane (paclitaxel albumin-bound nanoparticles), Genexol-PM (paclitaxel-loaded polymeric micelles)
Monoclonal Antibodies	Engineered antibodies that specifically target cancer cells, often conjugated with chemotherapy drugs or radioisotopes.	Trastuzumab (Herceptin), Pertuzumab, T-DM1 (Trastuzumab emtansine)
Polymer-Drug Conjugates	Polymers conjugated with chemotherapy drugs to improve pharmacokinetics and enhance tumor accumulation.	NDC-1308 (polymer-doxorubicin conjugate)
Nanoparticle Albumin-Bound (NAB) Technology	Albumin-bound nanoparticles designed to enhance drug solubility, stability, and tumor targeting.	Abraxane (paclitaxel albumin-bound nanoparticles)
Microspheres	Spherical microparticles loaded with chemotherapy drugs, providing sustained release and localized delivery.	SIR-Spheres (Yttrium-90 microspheres) for radioembolization
Immunoliposomes	Liposomes conjugated with targeting ligands or antibodies for specific recognition of cancer cells.	MM-302 (HER2-targeted liposomal doxorubicin)

to selectively target and destroy cancer cells. When used in conjunction with chemotherapy, it can offer several advantages in the fight against cancer, particularly in overcoming drug resistance and addressing tumor heterogeneity (Spring *et al.*, 2015). Here's an overview of this combination approach:

### Rationale for Combination Therapy

**Targeted Local Treatment:** Photodynamic therapy can be used to specifically target and destroy cancer cells at a localized site within the body.

**Enhanced Drug Delivery:** PDT can increase the permeability of tumor blood vessels, potentially improving the delivery of chemotherapy drugs to the tumor site.

**Overcoming Resistance:** Combining PDT with chemotherapy can help overcome resistance mechanisms that may develop with chemotherapy alone. PDT can damage drug-resistant cancer cells and sensitize them to chemotherapy.

**Addressing Tumor Heterogeneity:** Tumors are often composed of different cell populations with varying sensitivities to treatment. The combination therapy can target both sensitive and resistant tumor cell populations (Palmer *et al.*, 2017).

### Benefits of Combining Chemotherapy and PDT

**Synergistic Effects:** Chemotherapy and PDT can have synergistic effects, leading to more effective tumor cell killing when used together.

**Reduced Side Effects:** Lower doses of chemotherapy may be required when combined with PDT, potentially reducing the toxic side effects associated with chemotherapy.

**Selective Targeting:** PDT can be highly localized, sparing healthy tissues from damage and reducing collateral damage often seen with traditional chemotherapy.

**Enhanced Drug Uptake:** The increased vascular permeability caused by PDT can enhance the uptake of chemotherapy drugs into the tumor, improving their efficacy (Gonzalez *et al.*, 2009).

### Challenges and Considerations

**Optimal Sequencing:** Determining the best timing and sequence for administering chemotherapy and PDT is important to maximize their synergistic effects.

**Patient Selection:** Identifying the most suitable patients for combination therapy based on tumor type, location, and characteristics is crucial.

**Light Penetration:** The effectiveness of PDT may be limited by the depth at which light can penetrate tissues. This restricts its use to superficial or accessible tumors.

**Side Effects:** PDT can cause skin sensitivity to light (photosensitivity) and may require patients to avoid bright light for a period after treatment (Morton *et al.*, 2008).

**Research and Clinical Trials:** Ongoing research and clinical trials are necessary to refine the combination therapy protocols and assess their long-term effectiveness and safety.

In summary, combining chemotherapy with photodynamic therapy offers a promising approach to cancer treatment. This combination has the potential to enhance the effectiveness of chemotherapy, overcome drug resistance, and address tumor heterogeneity, while minimizing some of the side effects associated with traditional chemotherapy. However, careful patient selection, treatment planning, and ongoing research

are essential to optimize the use of this combination therapy in clinical practice (Bennett *et al.*, 2011).

### Nanoparticles and Gene Therapy Combinations: Revolutionizing Breast Cancer Treatment Strategies

Combining nanoparticles with gene therapy holds great promise in revolutionizing breast cancer treatment strategies. This innovative approach aims to enhance the targeted delivery of therapeutic genes to breast cancer cells, allowing for more precise and effective treatments.

#### Challenges and Considerations

**Safety:** Ensuring the safety of nanoparticles and the genetic material they carry is critical, as unintended genetic modifications could have adverse effects.

**Delivery Efficiency:** Optimizing the design of nanoparticles to improve gene delivery efficiency is an ongoing challenge.

**Patient Selection:** Identifying patients who are most likely to benefit from this combination therapy based on their breast cancer subtype and genetic profile is crucial.

**Immune Response:** The body's immune system may respond to nanoparticles and the genetic material, potentially limiting their effectiveness.

**Regulatory Approval:** Regulatory approval and clinical validation are necessary steps before this combination therapy can become widely available for breast cancer patients (Demirer *et al.*, 2021) (Figure 1).

## CHALLENGES AND LIMITATIONS

### Drug Resistance: Strategies to Overcome Resistance Mechanisms

Drug resistance is a significant challenge in the treatment of various diseases, including cancer, infectious diseases, and even some chronic conditions. Resistance can develop due to a variety of mechanisms, making it crucial to develop strategies to overcome or mitigate these resistance mechanisms (Huh *et al.*, 2011). Here are some key strategies to address drug resistance:

- Combination Therapy,
- Targeted Therapies,
- Immunotherapy,
- Dose Optimization,
- Drug Cycling,
- Drug Combinations with Resistance Reversal Agents,
- Genetic and Molecular Profiling,
- Patient Education and Adherence,

- Continued Research and Development,
- Combating Environmental Resistance.

### Toxicity and Side Effects: Enhancing Safety Profiles of Drug Delivery Systems

Enhancing the safety profiles of drug delivery systems is a critical aspect of drug development and patient care. Drug delivery systems are designed to improve the efficacy and specificity of drug treatments, while minimizing toxicity and side effects (Patra JK *et al.*, 2018). Here are several strategies to enhance the safety profiles of drug delivery systems:


- Targeted Drug Delivery,
- Localized Delivery,
- Sustained Release,
- Biocompatible Materials,
- Reduced Immunogenicity,
- Therapeutic Monitoring,
- Patient Education,
- Biodegradable Carriers,
- Minimizing Off-Target Effects,
- Co-Delivery of Supportive Agents,

### Biocompatibility and Immunogenicity: Addressing Immunological Challenges in Clinical Translation

Addressing immunological challenges related to biocompatibility and immunogenicity is crucial when translating new drug delivery systems and therapeutic modalities from preclinical research to clinical use. Biocompatibility refers to the compatibility of a medical device or drug delivery system with the body, while immunogenicity relates to the potential of a substance to provoke an immune response (4 Pires IS *et al.*, 2022). Here are strategies to tackle these challenges during clinical translation:

Preclinical Immunotoxicity Assessment,

- Immunogenicity Testing,
- Immunomodulator Design,
- Surface Modifications,
- Biodegradable Materials,
- Immune Evasion Strategies,
- Patient Stratification,
- Clinical Monitoring,
- Dose Adjustment,
- Regulatory Guidance,



**Figure 1:** Challenges and limitations in development of Drug Delivery System used in Breast Cancer.

- Patient Informed Consent,
- Post-Market Surveillance,

### Biocompatibility and Immunogenicity: Addressing Immunological Challenges in Clinical Translation

Immunological challenges related to biocompatibility and immunogenicity is crucial when developing and translating new medical products, including drug delivery systems and therapeutic agents, from preclinical research to clinical use. Biocompatibility refers to the compatibility of a medical product with the body's biological systems, while immunogenicity pertains to the potential of a substance to provoke an immune response (Younis *et al.*, 2022).

### RECENT ADVANCES AND FUTURE PERSPECTIVES

Recent advances in drug delivery systems for breast cancer treatment include targeted nanoparticles, liposomes, and Antibody-Drug Conjugates (ADCs). These systems enhance drug specificity, reduce side effects, and improve therapeutic outcomes. Additionally, smart drug delivery systems responsive to tumor microenvironment changes are being developed. Future prospects involve personalized treatments tailored to individual patient profiles, harnessing immunotherapy combined with precise drug delivery, and the integration of cutting-edge technologies

like nanomedicine and gene therapy. These advancements aim to enhance breast cancer therapy efficacy while minimizing systemic toxicity, representing a promising direction for breast cancer treatment.

### CONCLUSION

Drug Delivery Systems (DDS) stand at the forefront of innovation in breast cancer treatment, revolutionizing therapeutic strategies. The precision offered by targeted drug delivery minimizes collateral damage to healthy tissues, mitigating adverse effects associated with traditional chemotherapy. DDS enhances pharmacokinetics through controlled and sustained release, optimizing drug concentrations for prolonged efficacy. Overcoming drug resistance and enabling combination therapy, DDS addresses the multifaceted challenges posed by breast cancer heterogeneity. The personalized nature of DDS aligns with the principles of precision medicine, tailoring treatment to individual patients. While significant strides have been made, challenges such as drug stability and biocompatibility persist, necessitating ongoing research for further refinement. Despite these challenges, the potential impact of DDS in breast cancer is immense, offering hope for improved outcomes and enhanced quality of life for patients. As research continues to unravel the complexities of breast cancer, the evolution of drug delivery systems holds promise for reshaping the landscape of breast

cancer therapy, ushering in a new era of more effective, targeted, and patient-tailored treatments.

## ABBREVIATIONS

**EPR:** Enhanced Permeability and Retention; **HPV:** Human Papillomavirus; **NOCs:** N-nitroso Compounds; **PDT:** Photodynamic Therapy; **DDS:** Drug Delivery Systems; **ADCs:** Antibody-Drug Conjugates; **MMPs:** Matrix Metalloproteinases; **CAR-T:** Chimeric Antigen Receptor T cells; **NAB:** Nanoparticle Albumin-Bound; **MRI:** Magnetic Resonance Imaging; **CT:** Computed Tomography; **DNA:** Deoxyribonucleic Acid; **mRNA:** Messenger Ribonucleic Acid; **pH:** Potential of Hydrogen; **CRISPR-Cas:** Clustered Regularly Interspaced Short Palindromic Repeats–CRISPR Associated; **T-DM1:** Trastuzumab emtansine; **NDC-1308:** Polymer–doxorubicin conjugate; **SIR-Spheres:** Yttrium-90 microspheres; **MM-302:** HER2-targeted liposomal doxorubicin; **HER2:** Human Epidermal Growth Factor Receptor 2; **BALB/c 3T3:** Mouse embryonic fibroblast cell line; **HPV16:** Human Papillomavirus type 16; **E5:** Early protein 5; **E6:** Early protein 6; **E7:** Early protein 7.

## CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

## REFERENCES

- Afzal, M., Alharbi, K. S., Alruwaili, N. K., Al-Abassi, F. A., Al-Malki, A. A. L., Kazmi, I. et al. (Eds.). *Nanomedicine in treatment of breast cancer—A challenge to conventional therapy*2021. Elsevier.
- Ahmad, A., Khan, F., Mishra, R. K., & Khan, R. (2019). Precision cancer nanotherapy: Evolving role of multifunctional nanoparticles for cancer active targeting. *Journal of Medicinal Chemistry*, 62(23), 10475–10496. <https://doi.org/10.1021/acs.jmedchem.9b00511>
- Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhon, M. A., Ranasinghe, P., Block, L., Nicholson, W. K., Hutfless, S., Bass, E. B., & Bolen, S. (2011). Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. *Annals of Internal Medicine*, 154(9), 602–613. <https://doi.org/10.7326/0003-4819-154-9-20110530-00336>
- Blum, A. P., Kammeyer, J. K., Rush, A. M., Callmann, C. E., Hahn, M. E., & Gianneschi, N. C. (2015). Stimuli-responsive nanomaterials for biomedical applications. *Journal of the American Chemical Society*, 137(6), 2140–2154. <https://doi.org/10.1021/ja510147n>
- Cao, Z., Li, W., Liu, R., Li, X., Li, H., Liu, L., Chen, Y., Lv, C., & Liu, Y. (2019). pH- and enzyme-triggered drug release as an important process in the design of anti-tumor drug delivery systems. *Biomedicine and Pharmacotherapy*, 118, Article 109340. <http://doi.org/10.1016/j.biopha.2019.109340>
- Chow, E. J., Ness, K. K., Armstrong, G. T., Bhakta, N., Yeh, J. M., Bhatia, S. et al. (Eds.). *Current and coming challenges in the management of the survivorship population*2020. Elsevier.
- Coelho, J. F., Ferreira, P. C., Alves, P., Cordeiro, R., Fonseca, A. C., Góis, J. R., & Gil, M. H. (2010). Drug delivery systems: Advanced technologies potentially applicable in personalized treatments. *The EPMA Journal*, 1(1), 164–209. <https://doi.org/10.1007/s13167-010-0001-x>
- Demir, G. S., Silva, T. N., Jackson, C. T., Thomas, J. B., W Ehrhardt, D., Rhee, S. Y., Mortimer, J. C., & Landry, M. P. (2021). Nanotechnology to advance CRISPR–Cas genetic engineering of plants. *Nature Nanotechnology*, 16(3), 243–250. <https://doi.org/10.1038/s41565-021-00854-y>
- Diana, A., Carlino, F., Franzese, E., Oikonomidou, O., Crisciello, C., De Vita, F., Ciardiello, F., & Orditura, M. (2020). Early triple negative breast cancer: Conventional treatment and emerging therapeutic landscapes. *Cancers*, 12(4), Article 819. <https://doi.org/10.3390/cancers12040819>
- Esteva, F. J., Hubbard-Lucey, V. M., Tang, J., & Pusztai, L. (2019). Immunotherapy and targeted therapy combinations in metastatic breast cancer. *The Lancet. Oncology*, 20(3), e175–e186. [https://doi.org/10.1016/S1470-2045\(19\)30026-9](https://doi.org/10.1016/S1470-2045(19)30026-9)
- Ganz, P. A. (2008). Psychological and social aspects of breast cancer. *Oncology*, 22(6), 642–.
- Gao, W., Chan, J. M., & Farokhzad, O. C. (2010). pH-responsive nanoparticles for drug delivery. *Molecular Pharmaceutics*, 7(6), 1913–1920. <https://doi.org/10.1021/mp100253e>
- Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., Senn, H. J., & Panel members. (2011). Strategies for subtypes—Dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Annals of Oncology*, 22(8), 1736–1747. <https://doi.org/10.1093/annonc/mdr304>
- Gonzalez-Carmona, M. A., Bolch, M., Jansen, C., Vogt, A., Sampels, M., Mohr, R. U., van Beekum, K., Mahn, R., Praktijn, M., Nattermann, J., Trebicka, J., Branchi, V., Matthaei, H., Manekeller, S., Kalf, J. C., Strassburg, C. P., & Weismüller, T. J. (2019). Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. *Alimentary Pharmacology and Therapeutics*, 49(4), 437–447. *the British Photodermatology G. Guidelines for topical photodynamic therapy: update.* *British Journal of Dermatology*. 2008; 159(6): 1245-66. <https://doi.org/10.1111/apt.15050>
- He, M., Yang, T., Wang, Y., Wang, M., Chen, X., Ding, D., Zheng, Y., & Chen, H. (2021). Immune checkpoint inhibitor-based strategies for synergistic cancer therapy. *Advanced Healthcare Materials*, 10(9), Article e2002104. <https://doi.org/10.1002/adhm.202002104>
- Huang, P., Wang, X., Liang, X., Yang, J., Zhang, C., Kong, D., & Wang, W. (2019). Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. *Acta Biomaterialia*, 85, 1–26. <https://doi.org/10.1016/j.actbio.2018.12.028>
- Huh, A. J., & Kwon, Y. J. (2011). 'Nanoantibiotics': A new paradigm for treating infectious diseases using nanomaterials in the antibiotic-resistant era. *Journal of Controlled Release*, 156(2), 128–145. <https://doi.org/10.1016/j.jconrel.2011.07.002>
- Janzen, G. M., & Robinson, J. R. (2002). Sustained and controlled-release drug delivery systems. *Modern Pharmaceutics*, 4, 501–502.
- Kateb, B., Chiu, K., Black, K. L., Yamamoto, V., Khalsa, B., Ljubimova, J. Y., Ding, H., Patil, R., Portilla-Arias, J. A., Modo, M., Moore, D. F., Farahani, K., Okun, M. S., Prakash, N., Neman, J., Ahdoot, D., Grundfest, W., Nikzad, S., & Heiss, J. D. (2011). Nanoplatforams for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy? *Neuroimage*, 54 (Suppl. 1), S106–S124. <https://doi.org/10.1016/j.neuroimage.2010.01.105>
- Le, G. M., O'Malley, C. D., Glaser, S. L., Lynch, C. F., Stanford, J. L., Keegan, T. H. M., & West, D. W. (2005). Breast implants following mastectomy in women with early-stage breast cancer: Prevalence and impact on survival. *Breast Cancer Research*, 7(2), R184–R193. <https://doi.org/10.1186/bcr974>
- Lee, J. H., & Nan, A. (2012). Combination drug delivery approaches in metastatic breast cancer. *Journal of Drug Delivery*, 2012, Article 915375. <https://doi.org/10.1155/2012/915375>
- Masood, F. (2016). Polymeric nanoparticles for targeted drug delivery system for cancer therapy. *Materials Science and Engineering, C, Materials for Biological Applications*, 60, 569–578. <https://doi.org/10.1016/j.msec.2015.11.067>
- Minko, T., Dharap, S. S., Pakunlu, R. I., & Wang, Y. (2004). Molecular targeting of drug delivery systems to cancer. *Current Drug Targets*, 5(4), 389–406. <https://doi.org/10.2174/1389450043345443>
- Morton, C. A. McKe'nna KE, Rhodes LE, British Association of Dermatologists therapy G. Au.
- Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016). The immune system and cancer evasion strategies: Therapeutic concepts. *Journal of Internal Medicine*, 279(6), 541–562. <https://doi.org/10.1111/joim.12470>
- National research C. Mammography and beyond: Developing technologies for the early detection of breast cancer. (2001).
- Nedeljković, M., & Damjanović, A. (2019). Mechanisms of chemotherapy resistance in triple-negative breast cancer—How we can rise to the challenge. *Cells*, 8(9), Article 957. <https://doi.org/10.3390/cells8090957>
- Núñez, C., Capelo, J. L., Igrejas, G., Alfonso, A., Botana, L. M., & Lodeiro, C. (2016). An overview of the effective combination therapies for the treatment of breast cancer. *Biomaterials*, 97, 34–50. <https://doi.org/10.1016/j.biomaterials.2016.04.027>
- Núñez, C., Estévez, S. V., & del Pilar Chantada, M. (2018). Inorganic nanoparticles in diagnosis and treatment of breast cancer. *Journal of Biological Inorganic Chemistry*, 23(3), 331–345. <https://doi.org/10.1007/s00775-018-1542-z>
- Onzi, G., Guterres, S. S., Pohlmann, A. R., & Frank, L. A. (2021). Passive targeting and the enhanced permeability and retention (EPR) effect. *The ADME encyclopedia: A comprehensive guide on biopharmacy and pharmacokinetics* (pp. 1–13).
- Ostańska, E., Aebischer, D., & Bartusik-Aebischer, D. (2021). The potential of photodynamic therapy in current breast cancer treatment methodologies. *Biomedicine and Pharmacotherapy*, 137, Article 111302. <https://doi.org/10.1016/j.biopha.2021.111302>
- Palmer, A. C., & Sorger, P. K. (2017). Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. *Cell*, 171(7), 1678–1691.e13. <https://doi.org/10.1016/j.cell.2017.11.009>
- Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., Habtemariam, S., & Shin, H.-S. (2018). Nano based drug delivery systems: Recent developments and future prospects. *Journal of Nanobiotechnology*, 16(1), Article 71. <https://doi.org/10.1186/s12951-018-0392-8>

- Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2020). Nanocarriers as an emerging platform for cancer therapy. *Nano-Enabled Medical Applications*, 61–91.
- Petrilli, R., Pinheiro, D. P., de Cássia Evangelista de Oliveira, F., Galvão, G. F., Marques, L. G. A., Lopez, R. F. V., Pessoa, C., & Eloy, J. O. (2021). Immunoconjugates for cancer targeting: A review of antibody-drug conjugates and antibody-functionalized nanoparticles. *Current Medicinal Chemistry*, 28(13), 2485–2520. <https://doi.org/10.2174/0929867327666200525161359>
- Pinto, B. M., Trunzo, J. J., Reiss, P., & Shiu, S.-Y. (2002). Exercise participation after diagnosis of breast cancer: Trends and effects on mood and quality of life. *Psycho-oncology*, 11(5), 389–400. <https://doi.org/10.1002/pon.594>
- Pires, I. S., Hammond, P. T., & Irvine, D. J. (2021). Engineering strategies for immunomodulatory cytokine therapies: Challenges and clinical progress. *Advanced Therapeutics*, 4(8), Article 2100035. <https://doi.org/10.1002/adtp.202100035>
- Plosker, G. L. (2008). Pegylated liposomal doxorubicin: A review of its use in the treatment of relapsed or refractory multiple myeloma. *Drugs*, 68(17), 2535–2551. <https://doi.org/10.2165/0003495-200868170-00008>
- Schirmacher, V. (2019). From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). *International Journal of Oncology*, 54(2), 407–419. <https://doi.org/10.3892/ijo.2018.4661>
- Schlemmer, M., Lindner, L. H., Abdel-Rahman, S., & Issels, R. D. (2004). Principles, technology and indication of hyperthermia and part body hyperthermia. *Der Radiologe*, 44(4), 301–309. <https://doi.org/10.1007/s00117-004-1044-6>
- Sherman, K. A., Woon, S., French, J., & Elder, E. (2017). Body image and psychological distress in nipple-sparing mastectomy: The roles of self-compassion and appearance investment. *Psycho-oncology*, 26(3), 337–345. <https://doi.org/10.1002/pon.4138>
- Sourati, A., Ameri, A., & Malekzadeh, M. (2017). Acute side effects of radiation therapy. Springer. <https://doi.org/10.1007/978-3-319-55950-6>
- Spring, B. Q., Rizvi, I., Xu, N., & Hasan, T. (2015). The role of photodynamic therapy in overcoming cancer drug resistance. *Photochemical and Photobiological Sciences*, 14(8), 1476–1491. <https://doi.org/10.1039/c4pp00495g>
- Subhan, M. A., & Torchilin, V. P. (2019). Efficient nanocarriers of siRNA therapeutics for cancer treatment. *Translational Research: The Journal of Laboratory and Clinical Medicine*, 214, 62–91. <https://doi.org/10.1016/j.trsl.2019.07.006>
- Sutton, D., Nasongkla, N., Blanco, E., & Gao, J. (2007). Functionalized micellar systems for cancer targeted drug delivery. *Pharmaceutical Research*, 24(6), 1029–1046. <https://doi.org/10.1007/s11095-006-9223-y>
- Trimboli, R. M., Giorgi Rossi, P., Battisti, N. M. L., Cozzi, A., Magni, V., Zanardo, M., & Sardanelli, F. (2020). Do we still need breast cancer screening in the era of targeted therapies and precision medicine? Insights into Imaging, 11(1), Article 105. <https://doi.org/10.1186/s13244-020-00905-3>
- Ulldemolins, A., Seras-Franzoso, J., Andrade, F., Rafael, D., Abasolo, I., Gener, P., & Schwartz, S. (2021). Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. *Cancer Drug Resistance*, 4(1), 44–68. <https://doi.org/10.20517/cdr.2020.59>
- Vaidya, A., Jain, S., Pathak, K., & Pathak, D. (2018). Dendrimers: Nanosized multifunctional platform for drug delivery. *Drug Delivery Letters*, 8(1), 3–19. <https://doi.org/10.2174/2210303107666171109112523>
- Younis, M. A., Tawfeek, H. M., Abdellatif, A. A. H., Abdel-Aleem, J. A., & Harashima, H. (2022). Clinical translation of nanomedicines: Challenges, opportunities, and keys. *Advanced Drug Delivery Reviews*, 181, Article 114083. <https://doi.org/10.1016/j.ad dr.2021.114083>

**Cite this article:** Shah N, Sapra R, Suthar M, Sadhu P, Mandloi N, Kumari M, *et al.* A Brief Review of Drug Delivery System Used in Breast Cancer Therapies. *Int. J. Pharm. Investigation*. 2026;16(2):431-41.